TRENTON, N. J. (AP) — Drugmakers including the drugmaker Eli Lilly and Company (NYSE: LLY) announced Tuesday it will halt a program to promote Strattera, the first nonstimulant to treat attention deficit disorder (ADHD) — and help patients with the condition, as well as with a rare disorder — from their website and from other sources.
Lilly will stop promotional advertising for Strattera in the wake of reports of an unapproved marketing campaign for the drug, the company said in a statement.
“We are pleased that Eli Lilly and Company will continue to promote Strattera to its patients as a non-stimulant,” said Tadá standard manager of operations and chief operating officer of Lilly, who declined to be named because of the nature of the company’s promotional efforts.
“We are committed to the best future for patients with ADHD and the best future for Strattera,” said Lilly spokesman David A. Hofer.
Strattera was approved in 2002 for the condition, with approval from the U. S. Food and Drug Administration, which approved it in August 2003.
Lilly said in a statement that the decision is “partly based on our belief that marketing Strattera for ADHD may not be as safe and effective as it was previously approved by the FDA.”
The company also said it will continue to promote the drug, which is being sold by a different manufacturer, for as long as it is needed to treat the condition.
The drugmaker said it expects to launch the product in the U. in 2017, after the U. Food and Drug Administration approved it in 2002.
The company said it will continue to promote Strattera, and to “continue to educate patients and healthcare providers about the benefits and risks of this nonstimulant medication,” and to “examine the potential side effects of Strattera in patients with ADHD.”
Lilly said that the decision to halt promotional ads for Strattera was part of a broader effort to provide additional information about the drug and the risks and side effects of the unapproved drug. The company also said that it would continue to promote the drug, even if the drug has not been approved by the FDA.
Lilly’s marketing efforts are part of a broader effort to provide information about the drug and to inform the public of the drug’s potential side effects and risks, the company said.
In March, Lilly said it was “reviewing the data and information from our clinical trials to evaluate the safety and effectiveness of Strattera.”
The company said that Lilly will continue to provide updates to the data and information during the third quarter of the year.
In late March, Lilly said it was reviewing the data and information from its clinical trials. Lilly will continue to provide updates to the data and information during the third quarter of the year.
Lilly’s marketing efforts will be based on the information from its clinical trials and the information provided in its promotional materials. The company said that information will be provided to patients, and that it will continue to make any changes to the information provided in the promotional materials.
Tadac standard manager and chief operating officer of Lilly, Stephen A. Balsam, said, “It’s important to note that Eli Lilly and Company does not have an obligation to provide the information or any promotional material to consumers in any way.”
The company said in a statement that it was “reviewing the data and information from our clinical trials to evaluate the safety and effectiveness of Strattera.”
Lilly’s marketing efforts will be based on the information provided by the third quarter of the year.
In late March, Eli Lilly said it was reviewing the data and information from its clinical trials and the information provided in its promotional materials.
The company’s advertising and promotion efforts will be based on the information provided by the third quarter of the year.
Strattera is a medication used to treat adults with attention-deficit/hyperactivity disorder (ADHD) in the dose and duration as prescribed by their doctor. It is typically taken once a day. It can help improve your ability to pay attention and stay focused in the game of arms and legs. Strattera works by increasing the levels of norepinephrine in the brain, which helps improve attention and impulse control. This medication is classified as a dopamine antagonist. It is used alone or with other medications to treat ADHD symptoms. Strattera comes in a tablet form. It is taken once a day. It is usually well-tolerated. However, it is important to follow the dosage instructions carefully. It is essential to take Strattera at the same time every day. The doctor may adjust the dosage or recommend a different medication. It is important to note that Strattera is not a controlled substance and should only be taken under the supervision of a doctor. It is not a medication that can be used alone or with other drugs. It should be used as directed by a healthcare professional. In conclusion, Strattera is a medication used to treat ADHD. It works by increasing the levels of norepinephrine in the brain, which helps improve attention and impulse control. It can be taken together with other medication.
Strattera reviewsHow does this medication work?
This medication works by increasing the levels of norepinephrine in the brain, which helps improve attention and impulse control. Strattera belongs to a class of drugs called atypical antipsychotics. It is also approved for use in children. In addition to its use for ADHD, Strattera may be prescribed for other conditions as determined by your doctor.
How should I use Strattera?
The dosage of Strattera will vary depending on your individual needs. The usual recommended dose for adults with ADHD is 40 mg per day for 6 to 8 weeks. However, depending on the type and severity of the disorder, a higher dose may be prescribed. Do not exceed the recommended dose. Your doctor will determine the appropriate dosage for you depending on your health and response to treatment.
Can I take Strattera with food or alcohol?
It is not recommended to take Strattera with food or alcohol. It is best to avoid heavy or fatty foods to minimize the risk of side effects.
Can Strattera cause drowsiness or drowsiness?
Drowsiness or drowsiness may occur as your body adjusts to the medication. This can be a symptom of a more serious condition, such as a cardiovascular condition or a serious allergic reaction. Strattera may cause drowsiness or drowsiness when combined with alcohol. You should not drive a car or operate heavy machinery if you are drowsy or not feeling drowsiness. Do not drive a car without consulting a doctor if Strattera is prescribed for you.
Drug interactions and safety information
Certain medications may interact with Strattera and cause serious side effects. It is important to inform your doctor if you are taking any of the following medications: Aspirin, lithium, phenytoin, or valproate. Inform your doctor about all the medications you are taking, including over-the-counter medications and supplements, as Strattera may interact with them. If you are using any of the aforementioned medications, tell your doctor before starting Strattera. Also, tell your doctor if you have liver disease or if you have runny eyes after taking Strattera. This medication may affect the effect of other medications in the same category, such as verapamil, atazanavir, ritonavir, or indinavir.
What should I watch for while using Strattera?
Your doctor will evaluate your response to Strattera based on your medical history, your response to the medication, and your reaction to the medication. Do not stop taking Strattera suddenly without consulting your doctor, even if you start feeling well. If you stop taking Strattera suddenly, your symptoms may worsen or even stop. Your doctor will do a physical examination of your body to rule out any underlying conditions and may order tests to rule out drug reactions. Do not stop taking Strattera without consulting your doctor.
Do not abruptly stop taking Strattera without consulting your doctor or follow the dosage instructions carefully. Strattera is not recommended for people who have certain medical conditions, such as liver disease or kidney disease. Do not abruptly stop taking Strattera without consulting your doctor.
Strattera is a medication used to treat attention deficit hyperactivity disorder (ADHD) in children. It can be prescribed for children aged 4-11 with ADHD. Strattera belongs to a class of drugs called selective norepinephrine reuptake inhibitors. It works by increasing levels of norepinephrine in the brain to help improve attention and focus. It is not a stimulant and does not affect dopamine or noradrenaline levels. Strattera can be used to treat ADHD in adults.
The main side effects of Strattera include the following:
Before starting Strattera, your doctor will perform an in-depth interview with you to discuss the signs and symptoms of ADHD, and any other conditions that you may be at risk of developing. During this visit, your doctor may suggest lifestyle changes to help manage your symptoms and improve your overall well-being.
Your doctor will determine the most appropriate course of treatment. Some treatments include:
If you have any of the following symptoms, your doctor may prescribe an antidepressant or medication to treat them:
During this consultation, your doctor will decide if Strattera is right for you. Your doctor will also decide whether Strattera is appropriate for you.
Your doctor will be able to determine the most appropriate course of treatment. For more information, see the “Preliminary Treatment” section.
This article was first published in December 2017.
Read More About.Photo by.Photo credit:
Strattera is a medication used to treat attention deficit hyperactivity disorder (ADHD). It belongs to a class of drugs called selective norepinephrine reuptake inhibitors.
You can read more about ADHD here.
Medically reviewed by Jessica Swirble, PharmDLast updated on March 31, 2025
Drug Information| | |
atomoxetine is a non-stimulant medication primarily used to treat ADHD. It works by increasing the levels of norepinephrine and dopamine in the brain.
Atomoxetine is classified as a selective norepinephrine reuptake inhibitor (SNRI). It helps to increase norepinephrine and dopamine levels in the brain.
Atomoxetine is typically prescribed as an adjunct to other medication or therapy regimens.
The Controlled Substances can also help identify potential contraindications and provide guidance on the appropriate use of the drug.
Consult your healthcare provider for generic or specialty-drug product ratings, product mix information, and more.
Last updated on April 31, 2025
Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI).
The Controlled Substitutes website is used to identify medications and ratings that provide information on the medicines that are most appropriate for non-pharmacy-scale non-pharmacy-scale non-pharmacy-scale non-pharmacy-scale non-pharmacy-scale non-pharmacy-scale non-pharmacy-scale non-pharmacy-scale non-pharmacy-scale non-pharmacy ratings. It's also used to compare prices and see what kind of ratings are available for a particular medication.
|
SpecificationsPharmaceutical Product Name
atomoxetine
Indications
Atomoxetine is used for the treatment of attention-deficit hyperactivity disorder (ADHD), which is a neurodevelopmental condition characterized by difficulty in paying attention, focusing, and completing goal-directed tasks.
Atomoxetine is also used for the management of narcolepsy.
Atomoxetine belongs to the class of medications known as selective norepinephrine reuptake inhibitors (SNRIs).
SNRIs work by changing the levels of norepinephrine and dopamine in the brain. This decrease in the amount of these neurotransmitters helps to improve attention, focus, and impulse control.
Strattera (atomoxetine) is used in the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy, irritable bowel syndrome and schizophrenia. It works by causing the brain to release a neurotransmitter called norepinephrine, which in turn increases activity in the central nervous system and slows down the processing of messages.
Tell your doctor if you are taking the following or a similar drug called atomoxetine:
The following conditions may increase the risk of suicidal thoughts or behavior:
In the last 10 weeks, a sudden increase in activity in the brain has been linked to a sudden increase in suicidal thoughts and behavior. You should avoid activities that require you to be alert, such as driving or operating machinery.
Do not take more than the recommended dose of atomoxetine in a 24-hour period.
Tell your doctor if you take more than this or take this drug during pregnancy.
Tell your doctor if you smoke or have ever had an asthma attack or a history of allergic reactions to atomoxetine.
Stade de France Pharmacy